Sign in
Active, not recruitingPhase 4

Corticosteroid Meniscectomy Randomized Trial

Key facts

Who runs it
The Cleveland Clinic
Where
Boston and Cleveland, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
Phase
Phase 4
People taking part
150 people, planned
Started
27 May 2021
Expected to end
1 Aug 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Zilretta Injectable Product or Placebo
Record updated
31 August 2026

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Male or female age 40 and older
  • Scheduled for APM with enrolling surgeon
  • Arthroscopic evidence of structural OA including at least one surface with grade 2 chondral change
  • Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study

Who cannot take part

  • Injection with corticosteroid into affected knee in past 12 weeks
  • Bilateral surgery
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
  • Known or suspected hypersensitivity to Zilretta (or component of Zilretta) or triamcinolone acetonide
  • Injection with platelet rich plasma into affected knee in past 12 weeks
  • Females who are pregnant or nursing or plan to become pregnant during the study; men who plan to inseminate a partner or donate sperm
  • Kellgren and Lawrence Grade IV (severe OA; arthroplasty is typically preferred over APM in this setting)
  • Injection with hyaluronic acid into affected knee in past 24 weeks
  • Plan for cartilage resurfacing procedure (microfracture, autologous chondrocyte implantation, osteochondral autograft or allograft), ligament reconstruction or other open procedure
  • Unable to undergo MRI due to implanted medical device, aneurysm clamp, metal fragments in eye, etc
  • Absence of at least one area of grade 2 chondral change on diagnostic arthroscopy (patients without structural OA are excluded)

Where in United States

  • Bringham and Women's HospitalBoston, United States
  • Cleveland Clinic FoundationCleveland, United States

About the trial

What the trial wants to find out

Synovitis has an important role in the symptoms and progression of Osteoarthritis (OA). Inflamed synovium has been associated with both increased symptoms and increased progression in OA patients. Furthermore, synovitis observed during knee arthroscopy in our patients undergoing arthroscopic partial meniscectomy (APM) was associated with worse symptoms while adjusting for confounding factors.Therefore, a better understanding of synovitis as a predictor of outcome after APM and as a target for treatment is needed to improve outcomes in this patient population.

Read full original descriptionShow less

Triamcinolone has been shown to decrease synovitis-associated outcomes in both animal and human studies after anterior cruciate ligament (ACL) injury. In a porcine model of ACL injury, treatment with triamcinolone resulted in decreased formation of synovitis-related collagen breakdown products as well as decreased cellularity of the synovium.And in a trial of triamcinolone injected after ACL injury, similar findings of decreased C-telopeptide of type II collagen (CTX-II), associated with collagen type II breakdown, was found in knees administered triamcinolone compared to placebo controls.

The 2 groups in the trial

  • corticosteroidTreatment being tested

    Triamcinolone extended release (32 mg) administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy. * Knee injury and Osteoarthritis Outcome Score (KOOS) pain at 6 and 12 months * T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months * Morphologic grading of cartilage using the MOAKS score at 3 and 12 months * 3D bone shape from MRI Osteoarthritis Knee Score (MOAKS) using statistical shape modeling at 3 and 12 months * Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months

    Treatment: Zilretta Injectable Product or Placebo

  • PlaceboPlacebo, for comparison

    Normal saline of 5 mL administered as an intraarticular injection at the conclusion of arthroscopic partial meniscectomy. * KOOS pain at 6 and 12 months * T1ρ and T2 imaging of cartilage and meniscus at 3 and 12 months * Morphologic grading of cartilage using the MOAKS score at 3 and 12 months * 3D bone shape from MRI using statistical shape modeling at 3 and 12 months * Improvement in blood, serum and urine inflammatory biomarker profiles at 3 and 12 months

    Treatment: Zilretta Injectable Product or Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Injection After Arthroscopic Partial Meniscectomy
Record updated
31 August 2026